Tradestie Institutional Equity Comparison Engine

ABCL vs RAPT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ABCL Overall Edge

ABCL Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to AbCellera Biologics Inc. Common Shares (ABCL) driven by superior Valuation, Options & Structure while RAPT counters with relative strength in Growth & Margin, Momentum & Technical. Fundamentally, ABCL trades at 27.6x Forward P/E with -1550.0% operating margin (-76.3% YoY revenue) versus RAPT at N/M Forward P/E and 0.0% operating margin (-100.0% YoY). In options structure, ABCL sits in CONSOLIDATION (29th %ile IV; Dealer Gamma Walls on Pro) against RAPT sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ABCL
ABCL 27.6x vs RAPT N/M Fwd P/E
Growth & Margin Winner RAPT
Op Margin -1550.0% vs 0.0% ยท YoY -76.3% vs -100.0%
Momentum & Technical Winner RAPT
1Y +207.6% vs +480.2% ยท 52W Pos 68% vs 100%
Options & Structure Winner ABCL
CONSOLIDATION (29th %ile IV) vs UNCLASSIFIED (<1st %ile IV)
ABCL NASDAQ
AbCellera Biologics Inc. Common Shares
Pharmaceutical Preparations
$11.14
-3.08% 1D
Market Cap $3.8B
1M Return -5.63%
1Y Return +207.62%
Forward P/E 27.6x
Unified AI Score
63.3 / 100 BUY
Tech 57.0 Fund 58.0 Flow 67.0 Mom 54.0
RAPT NASDAQ
RAPT Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$58.02
+0.07% 1D
Market Cap $1.7B
1M Return +0.68%
1Y Return +480.2%
Forward P/E N/M
Unified AI Score
52.4 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 61.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ABCL +207.62% RAPT +480.2% Spread: +98.43 pp (RAPT Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ABCL TTM Op. Margin: -1550.0% RAPT TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABCL vs RAPT. Trailing 12-month operating profitability (ABCL -1550.0% vs RAPT 0.0%) and valuation multiples (ABCL 27.6x vs RAPT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ABCL (6) vs RAPT (4)
Institutional Metric ABCL RAPT Criterion Row Winner
Market Capitalization Scale $3.8B $1.7B Larger Scale ABCL
Trailing P/E Ratio Valuation 27.6x N/M Lower Multiple ABCL
Forward P/E Ratio Valuation 27.6x N/M Lower Multiple ABCL
Revenue Growth (YoY) Growth -76.3% -100.0% Higher Growth ABCL
Operating Margin (TTM) Profitability -1550.0% 0.0% Higher Margin RAPT
Net Profit Margin Profitability -248.8% 0.0% Higher Margin RAPT
Return on Equity (ROE) Capital Efficiency -17.3% -85.4% Higher ROE ABCL
52-Week Range Position Momentum 68% ($3โ€“$15) 100% ($1โ€“$58) Stronger Trend RAPT
Beta / 30D Volatility Risk Regime 2.30ฮฒ ยท 87% Vol -0.02ฮฒ ยท 2% Vol Lower Realized Risk RAPT
Unified Institutional Score Composite Signal 63.3 / 100 (BUY) 52.4 / 100 (HOLD) Higher Composite ABCL

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ABCL vs RAPT Buy Guide
ABCL CONSOLIDATION
34d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 29th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ABCL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
RAPT UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live RAPT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ABCL nor RAPT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.